Kura Oncology Inc (KURA) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Kura Oncology Inc   (NASDAQ: KURA)


Kura Oncology Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Kura Oncology Inc's ROI in the second quarter of 2026?
Kura Oncology Inc recorded a cumulative net loss of $-297 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -54.7%.

Within the Healthcare sector 489 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3659 to 3745.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -7.41 % 1.4 % 12.97 % 33.15 % 27.49 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 470 551 621 528 575
Return On Investment (TTM) -54.7 % -51.77 % -46.86 % -35.57 % -33.65 %
KURA's Overall Ranking # 3745 # 3659 # 2489 # 1195 # 2877
Seq. Investment Change TTM -4.64 % -4.33 % -2.46 % 4.06 % 4.43 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -297 -295 -279 -217 -197

KURA Company Profile >> Back to KURA Roi Comparisons >> See Annual KURA Return On Investment



Return On Investment KURA's Ranking
Within: No.
Industry # 209
Sector # 490
Overall # 3745

Return On Investment Statistics
High Average Low
-21.37 %
-1808.35 %
-83329.5 %
(Sep 30 2021)   (Sep 30 2014)



  News about Kura Oncology Inc Return on Investment ROI

Navigating the Therapeutic Frontier Kura Oncologys KOMZIFTI Approval Amidst Competitive Pressures

November 13, 2025

In recent developments within the pharmaceutical landscape, Kura Oncology and Kyowa Kirin s announcement of the FDA approval for KOMZIFTI (ziftomenib) marks a transformative moment for patients grappling with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). This approval not only represents the first and only once-daily targeted therapy for this patient demographic but reinforces the clinical implications of actionable genetic mutations in oncology. Actionable Genetic Drivers in AML NPM1 mutations are among the most prevalent genetic aberrations driving AML. Until the recent approval of KOMZIFTI, the treatment options for such patients were limited. This breakthrough highlights a significant evolution in precision medicine, where therapies are tailored to the genetic factors influencing disease progression. By facilitating treatment options that directly target molecular anomalies, the approval of KOMZIFTI is poised to enhance clinical outcomes for a cohort of patients historically burdened by limited options.





Financial Statements
Kura Oncology Inc's II. Quarter Investments $ 470 Millions KURA's Balance sheet
Kura Oncology Inc's II. Quarter Income $ -68 Millions Quarterly KURA's Income Statement
KURA's Income by Division See KURA's Income by Division


KURA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 621 681 407 430 507
Y / Y Investment Growth -8.81 % 67.3 % -5.21 % -15.24 % -17.64 %
Net Income in Millions -279 -174 -153 -136 -130
Y / Y Net Income Growth - - - - -
Annual Return On Investment -44.85 % -25.53 % -37.47 % -31.61 % -25.73 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
KURA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for KURA's Competitors
Subscribers only: Roi for Kura Oncology Inc's Suppliers
Subscribers only: Return On Investment for KURA's Customers

Other Ratios
KURA's Roa KURA's Inventory Turnover Ratio KURA's Growth Rates KURA's Dividend Statistics
KURA's Profitability Ratios KURA's Asset Turnover Ratio KURA's Dividend Growth
KURA's Roe KURA's Valuation Ratios KURA's Financial Strength Ratios KURA's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-12T06:19:57+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.